 Carcinoma, Intraductal, Noninfiltrating
"Carcinoma, Intraductal, Noninfiltrating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
| Descriptor ID |
D002285
|
| MeSH Number(s) |
C04.557.470.200.025.275 C04.557.470.200.240.187.250 C04.557.470.615.275
|
| Concept/Terms |
Carcinoma, Intraductal, Noninfiltrating- Carcinoma, Intraductal, Noninfiltrating
- Carcinoma, Intraductal
- Carcinomas, Intraductal
- Intraductal Carcinoma
- Intraductal Carcinomas
- DCIS
- Ductal Carcinoma In Situ
- Intraductal Carcinoma, Noninfiltrating
- Carcinoma, Noninfiltrating Intraductal
- Carcinomas, Noninfiltrating Intraductal
- Intraductal Carcinomas, Noninfiltrating
- Noninfiltrating Intraductal Carcinoma
- Noninfiltrating Intraductal Carcinomas
Atypical Ductal Hyperplasia- Atypical Ductal Hyperplasia
- Atypical Ductal Hyperplasias
- Ductal Hyperplasia, Atypical
- Ductal Hyperplasias, Atypical
- Hyperplasia, Atypical Ductal
- Hyperplasias, Atypical Ductal
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Intraductal, Noninfiltrating".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Glandular and Epithelial [C04.557.470]
- Carcinoma [C04.557.470.200]
- Adenocarcinoma [C04.557.470.200.025]
- Carcinoma, Intraductal, Noninfiltrating [C04.557.470.200.025.275]
- Carcinoma in Situ [C04.557.470.200.240]
- Breast Carcinoma In Situ [C04.557.470.200.240.187]
- Carcinoma, Intraductal, Noninfiltrating [C04.557.470.200.240.187.250]
- Neoplasms, Ductal, Lobular, and Medullary [C04.557.470.615]
- Carcinoma, Intraductal, Noninfiltrating [C04.557.470.615.275]
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Intraductal, Noninfiltrating".
This graph shows the total number of publications written about "Carcinoma, Intraductal, Noninfiltrating" by people in this website by year, and whether "Carcinoma, Intraductal, Noninfiltrating" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 1 | 0 | 1 | | 1997 | 0 | 1 | 1 | | 2000 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2007 | 1 | 1 | 2 | | 2008 | 2 | 1 | 3 | | 2009 | 3 | 0 | 3 | | 2011 | 3 | 0 | 3 | | 2012 | 1 | 0 | 1 | | 2013 | 4 | 1 | 5 | | 2014 | 2 | 0 | 2 | | 2015 | 4 | 0 | 4 | | 2016 | 3 | 0 | 3 | | 2017 | 4 | 0 | 4 | | 2018 | 1 | 1 | 2 | | 2021 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Intraductal, Noninfiltrating" by people in Profiles.
-
Brock EJ, Jackson RM, Boerner JL, Li Q, Tennis MA, Sloane BF, Mattingly RR. Sprouty4 negatively regulates ERK/MAPK signaling and the transition from in situ to invasive breast ductal carcinoma. PLoS One. 2021; 16(5):e0252314.
-
Cobleigh MA, Anderson SJ, Siziopikou KP, Arthur DW, Rabinovitch R, Julian TB, Parda DS, Seaward SA, Carter DL, Lyons JA, Dillmon MS, Magrinat GC, Kavadi VS, Zibelli AM, Tiriveedhi L, Hill ML, Melnik MK, Beriwal S, Mamounas EP, Wolmark N. Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2367-2374.
-
Doke K, Butler S, Mitchell MP. Current Therapeutic Approaches to DCIS. J Mammary Gland Biol Neoplasia. 2018 12; 23(4):279-291.
-
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Mar; 16(3):310-320.
-
Veenstra CM, Wallner LP, Jagsi R, Abrahamse P, Griggs JJ, Bradley CJ, Hawley ST. Long-Term Economic and Employment Outcomes Among Partners of Women With Early-Stage Breast Cancer. J Oncol Pract. 2017 11; 13(11):e916-e926.
-
Brown RJ, Sams S, Wolverton DE, Chong T, Borges VF, Rabinovitch RA, Murphy CD. Don't Be Fooled by DCIS. Oncology (Williston Park). 2017 07 15; 31(7):549-51, 560-1.
-
Stokes WA, Amini A, Jackson MW, Plimpton SR, Kounalakis N, Kabos P, Rabinovitch RA, Rusthoven CG, Fisher CM. Patterns of Fractionation and Boost Usage in Adjuvant External Beam Radiotherapy for Ductal Carcinoma in Situ in the United States. Clin Breast Cancer. 2018 06; 18(3):220-228.
-
Arthur DW, Winter KA, Kuerer HM, Haffty BG, Cuttino LW, Todor DA, Simone NL, Hayes SB, Woodward WA, McCormick B, Cohen RJ, Sahijdak WM, Canaday DJ, Brown DR, Currey AD, Fisher CM, Jagsi R, White J. NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-Year Toxicity Report From a Phase 2 Study of Repeat Breast-Preserving Surgery and 3-Dimensional Conformal Partial-Breast Reirradiation for In-Breast Recurrence. Int J Radiat Oncol Biol Phys. 2017 08 01; 98(5):1028-1035.
-
Agarwal A, Scott FI, Ahmad NA, Chandrasekhara V. Chronic immunosuppression does not potentiate the malignant progression of mucinous pancreatic cystic lesions. Pancreatology. 2016 Sep-Oct; 16(5):900-4.
-
Black SA, Nelson AC, Gurule NJ, Futscher BW, Lyons TR. Semaphorin 7a exerts pleiotropic effects to promote breast tumor progression. Oncogene. 2016 09 29; 35(39):5170-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|